List view / Grid view
Conspiracy theories about COVID-19 have been spreading since the early days of the outbreak. But how do we know whether a biological entity is artificially made or has occurred naturally? Marc Baiget Francesch explores the capabilities of current scientific approaches in terms of virus engineering and how this applies to…
A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology allows very sensitive, quick and cost-effective identification of cancer biomarkers. Nikki Withers spoke to Professor Carl Borrebaeck, who discusses how the researchers demonstrated the power of combining proteomics with genomics.
Next-generation sequencing (NGS) has become the method of choice for many researchers responding to infectious disease outbreaks and in the present coronavirus pandemic. Here, Pushpanathan Muthuirulan discusses the potential of NGS for rapid diagnosis and explores some of the emerging high-throughput approaches using NGS as a readout for the detection…
Genomics England has launched a next-generation genomic research platform that will play a key role in the response to COVID-19. It is hoped this research environment will transform how genomic data is made usable for global biopharma and academic scientists, providing world‑class patient data security, while enabling the flexibility required…
A new tool called COVID-3D that monitors SARS-CoV-2 genome mutations could aid drug and vaccine development, its creators say.
Not every step of CAR T-cell manufacturing can be tightly regulated, introducing some significant quality control challenges for companies developing CAR T cancer therapies
Human genome-produced RNA has been found on the surface of human cells, which researchers say could be easier for therapeutics to reach.
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
Adeno-associated virus (AAV)-mediated gene therapies allow for the treatment of a growing number of diseases; however, the presence of neutralising antibodies can lead to limitations of this technology, particularly for patients who may be excluded due to these pre-existing or developing neutralising antibodies. Recently, a study was published in Nature…
The study evaluating Down syndrome endothelial cells presented novel drug targets for leukaemia and suggested why DS patients may be at greater risk from the cancer.
Professor Giovanni Di Guardo discusses the relationship between animals and humans in regards to the transmission of SARS-CoV-2.
In this NGS In-Depth Focus: how next-generation sequencing (NGS) enables rapid detection of viruses and a novel NGS platform advancing genomics research.
In this In-Depth Focus find articles exploring the roles of key proteins implicated in Alzheimer's disease and a new technology enabling the identification of novel cancer biomarkers.
Included in this in-depth focus are articles on antibody therapeutics to treat COVID-19, how AAV antibodies can be neutralised, the role of antibodies in cancer therapy and bispecific antibodies for immuno-oncology drugs.
Intestinal organoids have been grown by researchers using stem cells from patient tissues that could lead to personalised transplants for children with intestinal failure.
